GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Doseology Sciences Inc (XCNQ:MOOD) » Definitions » Debt-to-Revenue

Doseology Sciences (XCNQ:MOOD) Debt-to-Revenue : 0.00 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Doseology Sciences Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Doseology Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was C$0.00 Mil. Doseology Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was C$0.00 Mil. Doseology Sciences's annualized Revenue for the quarter that ended in Mar. 2024 was C$0.14 Mil. Doseology Sciences's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.00.


Doseology Sciences Debt-to-Revenue Historical Data

The historical data trend for Doseology Sciences's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Doseology Sciences Debt-to-Revenue Chart

Doseology Sciences Annual Data
Trend Jun20 Jun21 Jun22 Jun23
Debt-to-Revenue
N/A N/A 46.63 1.19

Doseology Sciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.08 1.16 0.23 - -

Competitive Comparison of Doseology Sciences's Debt-to-Revenue

For the Biotechnology subindustry, Doseology Sciences's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Doseology Sciences's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Doseology Sciences's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Doseology Sciences's Debt-to-Revenue falls into.



Doseology Sciences Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Doseology Sciences's Debt-to-Revenue for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.043 + 0.008) / 0.043
=1.19

Doseology Sciences's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


Doseology Sciences Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Doseology Sciences's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Doseology Sciences (XCNQ:MOOD) Business Description

Traded in Other Exchanges
Address
116 - 5100 Anderson Way, Unit 197, Vernon, BC, CAN, V1T 0C4
Doseology Sciences Inc is a diversified life sciences company, on a mission to reimagine mental health therapies through innovation, technology and sustainability. With a focus on the psychedelic and non-psychedelic compounds, also sale of its branded functional mushroom products. Doseology offers cutting-edge therapeutic products and services, with the aim of making a meaningful impact on the mental health pandemic and improving overall health.

Doseology Sciences (XCNQ:MOOD) Headlines

No Headlines